The study from Thieme et al. demonstrated the promising activity of CG-806 in the MCL-PDX model via disrupting BCR signaling networks [158]; thus, this agent can be a potential alternative molecule to be tested in MCL cases. Here, BCR is linked to mantle cell lymphoma.